



LB04/3398



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 27 AUG 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 20 August 2004


BEST AVAILABLE COPY



11

Patents Form 1/77

Patents Act 1977
(Rule 16)



The
Patent
Office

1/77

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also find an explanatory leaflet from the Patent Office if you fill in this form)

1.	Your reference	44.95.81434		
2.	Patent application number (The Patent Office will fill in this part)	0318244.1		4 AUG 2003
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	Camurus AB Ideon, Gamma 1 Sölvegatan 41 SE-223 70 Lund Sweden		
	Patents ADP number (if you know it)			
	If the applicant is a corporate body, give country/state of incorporation	Sweden	8217762002	
4.	Title of the invention	Method		
5.	Name of your agent (if you have one)	Frank B. Dehn & Co.		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL		
	Patents ADP number (if you know it)	166001		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))			

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

-

Description

34 ✓

Claim(s)

2 ✓

Abstract

JML

Drawing(s)

7 + 7

10. If you are also filing any of the following, state how many against each item.

Priority documents

-

Translations of priority documents

-

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

-

Request for preliminary examination and search (Patents Form 9/77)

-

Request for substantive examination (Patents Form 10/77)

-

Any other documents (please specify)

-

11. I/We request the grant of a patent on the basis of this application.

Signature *Frank B. Deh* Date 4 August 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Julian Cockbain
020 7206 0600

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Method

The present invention relates to methods for the production of particles suitable for the delivery of active substances. More specifically, the invention relates to methods for the production of non-lamellar amphiphile-based particles.

Amphiphile-based formulations show considerable potential in the delivery of many substances, especially for *in vivo* delivery to the human or animal body. Because the amphiphile has both polar and apolar groups which cluster to form polar and apolar regions, it can effectively solubilise both polar and apolar compounds. In addition, many of the structures formed by amphiphiles/structuring agents in polar and/or apolar solvents have a very considerable area of polar/apolar boundary at which other amphiphilic compounds can be adsorbed and stabilised.

The formation of non-lamellar regions in the amphiphile/water, amphiphile/oil and amphiphile/oil/water phase diagrams is a well known phenomenon. Such phases include liquid crystalline phases such as the cubic P, cubic D, cubic G and hexagonal phases, which are fluid at the molecular level but show significant long-range order, and the L_3 phase which comprises a multiply interconnected bi-continuous network of bilayer sheets which are non-lamellar but lack the long-range order of the liquid crystalline phases. Depending upon their curvature, these phases may be described as normal (mean curvature towards the apolar region) or reversed (mean curvature towards the polar region).

The non-lamellar liquid crystalline and L_3 phases are thermodynamically stable systems. That is to say, they

are not simply a meta-stable state that will separate and/or reform into layers, lamellar phases or the like, but are the stable thermodynamic form of the mixture.

5 Both lamellar and non-lamellar systems have been investigated for their properties as carriers and/or excipients for dietary, cosmetic, nutritional, diagnostic and pharmaceutical agents but the non-lamellar systems are thought to have considerable
10 advantages in terms of their high internal surface area and bicontinuous polar and apolar regions. This has led to considerable investigation of non-lamellar phases particularly in controlled-release formulations and for solubilising relatively insoluble compounds.

15 As discussed above, bulk non-lamellar phase is typically a thermodynamically stable system. In addition, this bulk phase may be dispersed in a polar or non-polar solvent to form particles of a non-lamellar (especially
20 liquid crystalline) phase in a bulk solvent. This allows the advantages of bulk non-lamellar phases to be applied in situations where use of a bulk non-miscible phase would cause problems, such as in parenteral applications. Further control of a compound's release
25 profile may also be achieved by such a dispersion. In many cases, the liquid crystalline or L_3 phase is in thermodynamic equilibrium with the excess solvent and therefore dispersions of non-lamellar particles can be prepared.

30 A method for the formation of dispersed particles of non-lamellar phase in solvents such as water is described in US 5,531,925. Such particles have a non-lamellar liquid crystalline or L_3 interior phase and a
35 lamellar or L_2 surface phase and may also contain active ingredients.

Known particles of liquid crystalline or L₃ interior phase may be formed by methods such as adding to this phase a solution of surface-phase forming agent, stirring to form a coarse dispersion and fragmenting the resulting mixture.

In order to assess the presence of a liquid crystalline phase, the liquid crystalline order discussed above may be examined by use of small-angle X-ray diffraction (SAX), cryo-Transmission Electron Microscopy (cryo-TEM) or Nuclear Magnetic Resonance (NMR) spectroscopy studies. The sizes and size distributions of the dispersed particles may be examined by light scattering, particularly by use of laser light scattering instruments.

Dispersions containing active ingredients and particularly those for intravenous administration to the human or animal body are desirably colloidal, that is they should be of a particle size no greater than 10 μm , especially no greater than 5 μm and particularly no greater than 1 μm . If particles within the dispersion exceed this size then the dispersion may not be colloidally stable and there is a considerable risk of causing embolism when the preparation is administered intravenously. Furthermore, it is desirable that the distribution of particle sizes be narrow to maximise control over the release of any active agent. Where a particulate composition is to be administered by a method other than intravenously (e.g. orally, intramuscularly, subcutaneously, rectally or by inhalation), then the particle size need not be colloidal but it remains advantageous to provide a well characterised and reproducible particle size distribution in order to control the rate of decomposition of the particles and/or release of the active agents.

In addition to control over particle size, it is desirable to maximise the proportion of particles which are in the desired, non-lamellar, phase in order to maximise the beneficial effects of this in terms of controlled release and reproducibility. The proportion of lamellar particles such as mono- or multi-lamellar vesicles should therefore be minimised.

Known methods for the formation of dispersed particles of non-lamellar phase are highly effective, but typically produce a relatively broad distribution of particle sizes and a certain proportion of "contaminant" lamellar vesicular particles. Increasing the proportion of fragmenting and/or stabilising agent (e.g. surfactant, copolymer and/or protein) in the formulation or increasing the energy input of the homogenisation process may be used to narrow the particle size distribution but at the expense of increasing the proportion of lamellar particles. There is therefore a considerable need for methods by which a dispersion of non-lamellar particles may be formed having a narrow, colloidal, particle size distribution and a high proportion of non-lamellar particles.

The present inventors have now, unexpectedly established that by heating lamellar and/or non-lamellar particles of appropriate composition to an elevated temperature for a short period before cooling to room temperature, the distribution of particle sizes may be narrowed and/or the proportion of non-lamellar particles increased.

The present invention therefore provides a method for the production of (preferably colloidal) non-lamellar particles, said method comprising forming lamellar and optionally non-lamellar particles comprising at least one structuring agent, heating said particles to an

elevated temperature, followed by cooling, preferably to ambient temperature, wherein said heating is to a temperature and for a period sufficient to provide conversion of at least 50% of said lamellar particles to non-lamellar form, after cooling. This heating and cooling method may be carried out once, or as two, three, four or more sequential cycles of heating and cooling.

10 The present invention further provides a method for narrowing the particle size distribution (for example, as displayed by light scattering) of a sample of lamellar and/or non-lamellar particles comprising at least one structuring agent, said method comprising
15 heating said particles to an elevated temperature, followed by cooling, preferably to ambient temperature, wherein said heating is to a temperature and for a period sufficient to provide a narrowing of said particle size distribution after cooling. This heating
20 and cooling method may be carried out once, or as two, three, four or more sequential cycles of heating and cooling.

In a further aspect, the present invention provides non-lamellar particles comprising at least one structuring agent formed or formable by forming lamellar and optionally non-lamellar particles comprising at least one structuring agent, heating said particles to a temperature at which conversion to non-lamellar
25 particles takes place for a period sufficient to provide conversion of at least 50% of said lamellar particles to non-lamellar form, followed by cooling, preferably to ambient temperature. The particles may be non-colloidal (e.g. 10-200 μm), for example where the formulation is
30 to be suitable for non-intravenous use, but are preferably colloidal.
35

As use herein, the term "non-lamellar" is used to indicate a normal or reversed liquid crystal phase (such as a cubic or hexagonal phase) or the L₃ phase or any combination thereof. Where a particle is described as having a non-lamellar phase or form, this indicates that at least the internal region of the particle should adopt this form. The particles will generally have two distinct regions, an internal region and a surrounding surface region. The surface region, even in a "non-lamellar" particle will typically be lamellar or crystalline. In contrast, a "lamellar" particle, as described herein is a particle having a solvent, rather than non-lamellar, core-region.

The term "lamellar particles" is used herein to indicate vesicular particles characterised in that they comprise one or more outer lamellar bilayers of amphiphile, surrounding an inner solvent compartment.

The temperature to which the particles must be heated in order to provide the effect of the present invention will be readily established by one of skill in the art. For example, a sample of lamellar particles may be heated to a particular temperature for 4 hours and subsequently cooled to ambient temperature. The SAX scattering pattern of the sample before and after heat treatment may then be compared and the results compared for the presence of peaks corresponding to, for example, reversed cubic or hexagonal phase. Similarly, the length of time required for conversion at any particular temperature may be assessed by heating samples for set times and examining any changes in SAX scattering.

Typically, samples will be heated to a temperature in the range 75 to 200°C, preferably 85 to 150°C, more preferably 96 to 140°C. The most preferred temperature range is 100 to 130°C.

It has been surprisingly established that the temperature cycling method of the present invention functions without the need for the equilibrium form of the composition to be non-lamellar at the elevated temperature. For example, a cubic phase may be the equilibrium condition for a composition at temperatures from ambient to 90°C and the elevated temperature be 100°C. At this elevated temperature, the equilibrium condition for a composition may not be non-lamellar. For example, the equilibrium condition for the composition at the elevated temperature may be lamellar, micellar (e.g. L1, L2) or isotropic.

Thus, the present invention also provides a method for the production of (preferably colloidal) non-lamellar particles, said method comprising forming lamellar and optionally non-lamellar particles comprising at least one structuring agent, heating said particles to an elevated temperature at which temperature the equilibrium form of the particles is not non-lamellar (preferably lamellar, micellar (e.g. L1, L2), or isotropic), followed by cooling, preferably to ambient temperature, wherein said heating is to a temperature and for a period sufficient to provide conversion of at least 50% (by particle number) of said lamellar particles to non-lamellar form, after cooling. This heating and cooling method may be carried out once, or as two, three, four or more sequential cycles of heating and cooling.

Typical periods of heating at an elevated temperature are relatively short and will generally be between 1 minute and 4 hours, more typically between 2 minutes and 1 hour. Periods of between 2 and 30 minutes are preferred, particularly between 5 and 20 minutes. The period may optionally include a period for equilibration, typically 1-10 minutes.

The components of the formulations include at least one structuring agent (typically an amphiphile) and will generally also include a fragmentation agent (which may
5 also be an amphiphile, such as a surfactant, copolymer and/or protein). In addition, the formulations of the invention may include protein, drug, nutrient, cosmetic, diagnostic, pharmaceutical, vitamin, or dietary agents at a level sufficient to be effective without disrupting
10 the phase behaviour of the composition in such a way that a non-lamellar phase is no longer formed. These are referred to herein as "active agents". Under some circumstances the structuring agent or fragmentation agent may also be an active agent. It is preferable
15 that the thermodynamic equilibrium state of the component mixture of the formulation, optionally in the presence of a solvent (such as water) is a non-lamellar phase such as the normal or reversed cubic or hexagonal phases or L_3 phase.

20 The term structuring agents, as used herein in the methods and compositions of the invention, are any agents that are capable of forming a non-lamellar phase, optionally in the presence of other agents such as
25 amphiphiles and/or fragmentation agents. Structuring agents will generally have at least one polar, hydrophilic group and at least one non-polar, hydrophobic group.

30 Examples of polar groups are well known (see e.g. US published patent application number 20020153509) and include anionic groups such as carboxylates, phosphonates, sulphates and sulphonates, non-ionic
35 groups such as alcohols, polyols (eg sugars, glycerol etc) and esters, cationic groups such as quaternary ammonium compounds, pyridinium salts and quaternary phosphonium salts and zwitterionic groups such as

phospholipid head groups (e.g phosphatidyl-choline etc.), ammonioacetates, ammonio-alkanesulphonates and trialkylaminoalkylphosphate esters.

5 Examples of non-polar groups include C₆-C₃₂ alkyl and alkenyl groups, which are typically present as the esters of long chain carboxylic acids. These are often described by reference to the number of carbon atoms and the number of unsaturations in the carbon chain. Thus,
10 CX:Y indicates a hydrocarbon chain having X carbon atoms and Y unsaturations. Examples particularly include caproyl (C₆:0), capryloyl (C₈:0), capryl (C₁₀:0), lauroyl (C₁₂:0), myristoyl (C₁₄:0), palmitoyl (C₁₆:0), phytanoly (C₁₆:0), palmitoleoyl (C₁₆:1), stearoyl
15 (C₁₈:0), oleoyl (C₁₈:1), elaidoyl (C₁₈:1), linoleoyl (C₁₈:2), linolenoyl (C₁₈:3), arachidonoyl (C₂₀:4), behenoyl (C₂₂:0) and lignoceroyl (C₂₄:9) groups. An amphiphile will typically have one or two non-polar "tail" groups (mono-acyl and di-acyl lipids
20 respectively) but may have three, four or more hydrophobic groups.

Examples of structuring agents suitable for use in the present invention include all natural lipids, all
25 synthetic lipids, all surfactants, all copolymers, all proteins (in particular caseins and albumin), all hydrotropes, all alcohols, all other additives that may form or facilitate formation of non-lamellar structures. Preferred agents are glycerides (e.g. monoglycerides, diglycerides, and triglycerides), di- and
30 polyglycerolesters of glycerides (e.g. diglycerol monooleate, diglycerol monocaprates), natural fats and oils (e.g. soybean oil, coconut oil, corn oil, castor oil, sunflower oil), fractionated oils (e.g.
35 fractionated coconut oil, Miglyol® (Condea)), transesterified oils (e.g. Maizine®), transesterification products of oils and PEG (e.g.

ethoxylated castor oil (e.g. Cremophor® EL (BASF)),
ethoxylated hydrogenated castor oil (e.g. Cremophor®
RH-40 (BASF)), ethoxylated corn oil (e.g. Labrafil® M
2125 CS (Gattefossé)), acetylated monoglycerides, fatty
5 acids (e.g. C6-C26 saturated and unsaturated fatty
acids), fatty alcohols (e.g. phytantriol (3,7,11,15-
tetramethyl-1,2,3-hexadecantriol)), ether lipids (e.g.
monooleyl glyceryl ether), natural and synthetic
phospholipids (e.g. egg lecithin, soya lecithin,
10 hydrogenated lecithin, phosphatidyl choline,
phosphatidyl ethanolamine, phosphatidyl serine,
phosphatidyl glycerol, phosphatidic acid),
lysophospholipids (e.g. lyso-lecithin, lyso-phosphatidyl
choline, lyso-oleyl phosphatidyl choline),
15 phospholipid-analogous compounds (e.g. those disclosed
in US 6344576), sterols and sterol derivatives (e.g.
cholesterol, sitosterol, lanesterol and their esters,
especially with PEG or fatty acids), galactolipids (e.g.
digalactosyl diacylglycerol, monogalactosyl
20 diacylglycerol), sphingolipids (e.g. sphingomyelin);
nonionic surfactants, in particular ethoxylated
surfactants such as PEG-fatty acid mono- and diesters
(e.g. of the Crodet® (Croda), Cithrol® (Croda), Nikkol®
(Nikko), Myrj® (ICI) series, Solutol® HS 15 (BASF)), PEG
25 glycerol fatty acid esters (e.g. Tagat® L and O
(Goldschmidt), Glycerox® L series (Croda), Capmul® EMG
(Abitec)), transesterification products of oils and PEG
(e.g. of the Labrafil® (Gattefossé), Cremophor® (BASF)
Crovol® (Croda) and Nikkol® HCO (Nikko) series) ,
30 PEG-sorbitan fatty acid esters (e.g. Tween® 20, Tween®
80 and other polysorbates of the Tween® series (ICI)),
PEG alkyl esters (e.g. of the Brij® (ICI) and Volpo®
(Croda) series), PEG alkyl phenol surfactants (e.g. of
the Triton X and N series (Rohm & Haas); polyglycerised
35 fatty acids (e.g. Nikkol® Decaglyn (Nikko), Plurol®
Oleique (Gattefossé)), propylene glycol fatty acid
esters), propylene glycol fatty acid esters (e.g.

Capryol® 90 (Gattefossé), Lutrol® OP2000 (BASF), Captex® (Abitec), glycerol/propylene glycol fatty acid esters (e.g. Arlacel® 186 (ICI)), sorbitan fatty acid esters (e.g. of the Span® (ICI) and Crill® (Croda) series),
5 sugar esters (e.g. of the SUCRO ESTER® (Gattefossé) and Crodesta® (Croda) series),
polyoxyethylene-polyoxypropylene block copolymers (so-called poloxamers, e.g. of the Pluronic® (BASF), Synperonic® (ICI) and Lutrol® (BASF) series), copolymers
10 of ethylene oxide and butylene oxide; anionic surfactants including fatty acid salts, bile salts (e.g. sodium cholate, sodium glycocholate, sodium taurocholate), carboxylates such as ether carboxylates, succinylated monoglycerides, mono/diacetylated tartaric
15 acid esters of mono- and diglycerides, citric acid esters of mono- and diglycerides, glyceryl-lacto esters of fatty acids, acyl lactylates, alginate salts, propylene glycol alginate; cationic surfactants
20 including ethoxylated amines (e.g. polyoxyethylene-15 coconut amine), betaines (e.g. N-lauryl-N,N-dimethylglycine), alkylpyridinium salts, quarternary ammonium salts such as hexadecyl triammonium bromid, decyl trimethyl ammonium bromide, cetyl
25 trimethyl ammonium bromide; zwitterionic surfactants including trimethylammonioethylalkylphosphonates (e.g. the examples disclosed in US 6344576); and all mixtures thereof. The most preferred structuring agents are monooleate, monolinoleate, glyceryl dioleate, dioleoyl
30 phosphatidyl ethanolamine (DOPE), dioleoyl phosphatidylcholine (DOPC) and phytantriol, and mixtures of these with up to 50% fatty acids, in particular oleic acid and linoleic acid, polysorbate 80 (Tween® 80), polyethylene glycol 660 12-hydroxystearate (Solutol® HS
35 15), or lyso-phospholipids, especially lyso-oleoyl phosphatidylcholine (LOPC).

Often the structure forming agent component will contain components in the form of extracted and purified natural products and will thus contain a mixture of related compounds. Soy bean phosphatidyl choline, for example
5 is a mixture of compounds having around 60-75% C18:2 acyl groups, around 12-16% C16:0 and the balance others. Similarly, commercial glycerol monooleate is typically at least 90% monoglyceride but contains small amounts of diglyceride and free fatty acid, with the acyl groups
10 being over 60-90% C18:1, 5-10% saturated and the remainder largely higher unsaturated acyl groups. Different commercial preparations will also vary slightly as indicated in the Examples below.

15 A highly preferred structuring agent for use in the present invention is commercially available glycerol monooleate (GMO). As indicated above, this is largely monoglyceride with an oleoyl (C18:1) acyl chain but contains certain amounts of other compounds. These are
20 included in the term "glycerol monooleate" or "GMO" as used herein. Commercial preparations of GMO include GMOrphic-80 and Myverol 18-99 (available from Eastman Kodak), Rylo MG 19 and Dimodan DGMO (available from Danisco). Any of the structuring agents may be used
25 alone or in combination with one or more other structuring agents.

The fragmentation agent for use in the method of the invention will be agents which aid the dispersal of the
30 non-lamellar phase into particles or stabilise such particles. Typically a fragmentation agent will be a surfactant such as an amphiphilic block copolymer.

Important fragmentation agents include all natural
35 lipids, all synthetic lipids, all surfactants, all copolymers, all proteins (in particular caseins and albumin), all hydrotropes, all alcohols and all other

additives that may facilitate fragmentation spontaneously or with the aid of externally applied forces and pressures and contribute to stabilisation. This includes also nanoparticles and combinations of polymer and nanoparticles (see e.g. WO 99/12640).

Suitable copolymers for use as fragmentation agents may have blocks comprising polyoxyalkylenes, polyvinylpyrrolidone, polyvinylacetate, polyvinylalcohol, polyesters, polyamides and/or polyalkenes. The block copolymer will comprise at least two blocks of polymer having different degrees of hydrophilicity. Certain proteins (such as casein) are also of amphiphilic character and may be used as fragmentation agents. Where an active agent is an amphiphilic protein, this may act as both the active agent and the fragmentation agent, or may be included in addition to another active agent and/or fragmentation agent.

Preferred examples of amphiphilic block copolymers are poloxamers, which comprise at least one block of polyoxyethylene and block of polyoxypropylene. The most preferred fragmentation agents are poloxamer 407 (e.g. Pluronic® F127, BASF), poloxamer 188 (e.g. Pluronic® F68, BASF), and polysorbate 80 (e.g. Tween® 80, ICI).

The fragmentation agent will be present at a level sufficient to bring about the fragmentation of the structuring agent and/or to stabilise the fragmented non-lamellar phase particles. Such fragmentation may be spontaneous or may require physical fragmentation such as by shearing and/or ultrasonication. It is preferable that sufficient fragmentation agent is present that the non-lamellar particles are physically stable.

Active agents suitable for inclusion in the methods and

formulations of the present invention include human and veterinary drugs and vaccines, diagnostic agents, cosmetic agents, nutrients, dietary supplements etc. Examples of suitable drugs include antibacterial agents such a β -lactams or macrocyclic peptide antibiotics, anti fungal agents such as polyene macrolides (e.g amphotericin B) or azole antifungals, anticancer and/or anti viral drugs such as nucleoside analogues, paclitaxel and derivatives thereof, anti inflammatorys, such as non-steroidal anti inflammatory drugs, cardiovascular drugs including cholesterol lowering and blood-pressure lowering agents, analgesics, antidepressants including serotonin uptake inhibitors, vaccines and bone modulators. Diagnostic agents include radionuclide labelled compounds and contrast agents including X-ray, ultrasound and MRI contrast enhancing agents. Nutrients include vitamins, coenzymes, dietary supplements etc. The active agents for use in the present invention will generally not be poloxamers or acylglycerols.

Preferred active agents include human and veterinary drugs selected from the group consisting of peptides such as adrenocorticotrophic hormone (ACTH) and its fragments, angiotensin and its related peptides, antibodies and their fragments, antigens and their fragments, atrial natriuretic peptides, bioadhesive peptides, Bradykinins and their related peptides, calcitonins and their related peptides, cell surface receptor protein fragments, chemotactic peptides, cyclosporins, cytokines, Dynorphins and their related peptides, endorphins and P-lidotropin fragments, enkephalin and their related proteins, enzyme inhibitors, fibronectin fragments and their related peptides, gastrointestinal peptides, growth hormone releasing peptides, immunostimulating peptides, insulins and insulin-like growth factors, interleukins,

luteinizing hormone releasing hormones (LHRH) and their
related peptides, melanocyte stimulating hormones and
their related peptides, nuclear localization signal
related peptides, neurotensins and their related
5 peptides, neurotransmitter peptides, opioid peptides,
oxytocins, vasopressins and their related peptides,
parathyroid hormone and its fragments, protein kinases
and their related peptides, somatostatin and their
related peptides, substance P and its related peptides,
10 transforming growth factors (TGF) and their related
peptides, tumor necrosis factor fragments, toxins and
toxoids and functional peptides such as anticancer
peptides including angiostatin, antihypertension
peptides, anti-blood clotting peptides, and
15 antimicrobial peptides; selected from the group
consisting of proteins such as immunoglobulins,
angiogenins, bone morphogenic proteins, chemokines,
colony stimulating factors (CSF), cytokines, growth
factors, interferons, interleukins, leptins, leukemia
20 inhibitory factors, stem cell factors, transforming
growth factors and tumor necrosis factors; selected from
the group consisting of antivirals, steroidal
antiinflammatory drugs (SAID), non-steroidal
anti-inflammatory drugs (NSAID), antibiotics,
25 antifungals, antivirals, vitamins, hormones, retinoic
acid, prostaglandins, prostacyclins, anticancer drugs,
antimetabolic drugs, mitotics, cholinergics, adrenergic
antagonists, anticonvulsants, antianxiety agents,
tranquilizers, antidepressants, anesthetics, analgesics,
30 anabolic steroids, estrogens, progestones,
glycosaminoglycans, polynucleotides, immunosuppressants
and immunostimulants, cardiovascular drugs including
lipid lowering agents and blood-pressure lowering
agents, bone modulators; vaccines, vaccine adjuvants,
35 immunoglobulins and antisera; diagnostic agents;
cosmetic agents, sunscreens and self-tanning agents;
nutrients; dietary supplements; herbicides, pesticides,

and repellents. Further examples of active agents can be found for instance in Martindale, The Extra Pharmacopoeia.

5 In the methods of the invention, particles comprising a structuring agent are formed prior to one or more heat treatment cycles. This pre-formulation will typically be in the form of a dispersion and may be carried out by established methods, such as those indicated in the
10 present Examples and in US 5,531,925, WO 02/02716, WO 02/068561, WO 02/066014 and WO 02/068562. The disclosures of these and all references cited herein are hereby incorporated herein by reference. Such methods include adding an amphiphile/water liquid crystal phase
15 to an aqueous solution of fragmentation agent and optionally a lipid (such as PC) and either allowing natural fragmentation of the mixture or accelerating the process with, for example, mechanical agitation, vortexing, roto-stator mixing, high-pressure
20 homogenization, microfluidisation and/or ultrasound.

Since the method of the present invention can be used to convert lamellar particles to non-lamellar form, it is not essential that the pre-preparation particles be non-lamellar. They should, preferably, be formulated such
25 that the thermodynamically stable state is non-lamellar. Where present, the active agent may be incorporated into the particles prior to and/or after heat cycling. Where more than one heat cycle is used, the active agent may
30 also or alternatively be incorporated between cycles. Where the active agent is heat sensitive (e.g. peptide or protein) the active agent is preferably incorporated after heat cycling is complete.

35 Prior to, and/or after heat-cycling, the particles may be concentrated (e.g. by ultrafiltration or dialysis) and/or dried, for example by spray drying, fluid bed

drying or freeze drying. In the case of dried particles, the drying process may be followed by particle size enlargement through single or repeated agglomeration and granulation steps. The concentrated, dried and/or agglomerated particle formulations thus formed may be used as such or hydrated and/or dispersed to yield non-lamellar particle dispersions suitable for use in the delivery of active substances, especially in vivo. Such concentrated, dried and/or agglomerated particle formulations and the dispersions resulting from their re-suspension/hydration form a further aspect of the present invention.

In a preferred aspect of the invention, an initial pre-formulation, prior to heat treatment, is formed in which the particles will preferably be small colloidal sized particles, for example in the range 0.02 to 0.2 μm . Preferably the mean particle size for the small colloidal particles will be 0.05 to 0.15 μm in this pre-formulation. This small particle size can be achieved by known methods, as discussed above, but such methods result in a relatively large proportion of lamellar phase particles. At least one heat treatment cycle may then be applied to the pre-formulation so as to both convert the bulk of the lamellar particles to non-lamellar form and preferably also to narrow the particle size distribution. In this process, the mean particle size typically increases but the distribution of particle sizes is reduced. In this method, at least 50% (by particle number) of the lamellar particles should be converted to non-lamellar form. Preferably, at least 75% of the lamellar particles will be converted, more preferably at least 85% (e.g. 90%). It is most preferable that the treatment method convert 99% or more of the lamellar particles to a non-lamellar form.

The presence of particles in non-lamellar form will

preferably be assessed from a set of cryo-transmission electron microscopy particle images, preferably showing a sample of more than 50, preferably more than 100 particles. Example images are shown in Figures 3 and 4.

5 The presence of non-lamellar particles may also be assessed by X-ray scattering experiments.

After treatment with one or more heating and cooling cycles, the final particles should be in the colloidal size range. These will typically have an average (mode) particle size in the range 0.2 to 0.8 μm , more preferably 0.3 to 0.6 μm . It is particularly important that preparations for use in intravenous administration should not contain particles in the non-colloidal range.

10
15 This may be achieved by using the method of the invention, beginning with small colloidal particles as described above. Alternatively, or in addition, the particles, preferably after heat cycling, may be filtered in order to remove non-colloidal particles.

20

The samples of particles formed by the present invention have a greater proportion of non-lamellar particles and/or a narrower distribution of colloidal particle sizes than has been achieved by previous methods. Such particles therefore form a further aspect of the invention, as do dispersions thereof. The particles formed or formable by the method of the invention may be used in the production of nutritional, dietary, cosmetic, diagnostic or pharmaceutical compositions by known methods using well known carriers, excipients and other ingredients. In the case of pharmaceutical compositions, the particles will be formulated with at least one pharmaceutically acceptable carrier or excipient and may be formed into tablets, capsules and so forth. The particles may also be formulated as a pre-prepared dispersion in an acceptable liquid, such as water, or dried and sealed in sterile containers for re-

25
30
35

suspension prior to administration.

5 In the formulations formed or formable by the method of
the present invention, at least 75% (by volume) of the
particles will preferably be non-lamellar. More
preferably, at least 85% and most preferably at least
95% of particles in the formulation will be non-
lamellar, as measured by volume. This measurement may
be made by, for example, laser diffraction, preferably
10 combined with cryo-TEM or SAXS (to confirm the non-
lamellar particle structure) following laser
diffraction.

15 In a further aspect, the present invention thus provides
a formulation of (preferably colloidal) particles
comprising at least one structuring agent, wherein at
least 75% of the particles, preferably at least 85% and
most preferably at least 95% of particles (as measured
by volume) in the formulation are non-lamellar (e.g. as
20 judged by laser diffraction combined with cryo-TEM or
SAXS). In colloidal formulations, the average (mode)
particle size will typically be in the range 0.3 to 0.6
 μm , for example as determined by light scattering
methods (e.g. laser diffraction). Preferably, no more
25 than 1% of particles will be outside the range 0.05 to
1.5 μm , more preferably, not more than 0.1% will be
outside this range, and most preferably no detectable
(by laser diffraction) proportion of particles will be
outside this range. In non-colloidal formulations the
30 average (mode) particle size will typically be in the
range 10 to 200 μm .

Furthermore, the colloidal formulations prepared by the
method of the present invention are physically stable to
35 storage over extended periods at ambient temperature.
Such formulations should be stable both in terms of
phase behaviour and particle size for periods of at

least 3 months at room temperature, preferably at least 6 months and more preferably 12 months or more.

The invention will be illustrated below by the following non-limiting examples and the accompanying figures in which:

Figure 1 shows the particle size distribution of a sample of 12% poloxamer before and after heat treatment;

Figure 2 shows the particle size distribution of a sample of 8% poloxamer before and after heat treatment;

Figure 3 shows a cryo-transmission electron micrograph of a sample without heat treatment;

Figure 4 shows a cryo-transmission electron micrograph of a sample after heat treatment;

Figure 5 shows the particle size of a sample before and after heat treatment for various periods;

Figure 6 shows the particle size distribution of samples before and after heating to 80°C and 121°C;

Figure 7 shows the particle size distribution of a sample before and after heat treatment at various temperatures;

Figure 8 shows the effect of heat treatment at varying poloxamer concentrations;

Figure 9 shows the effect of heat treatment of compositions containing two different poloxamer types;

Figure 10 shows small angle X-ray scattering (SAXS) patterns for two samples, containing two different

poloxamer types, after heat treatment;

Figure 11 shows the effect of storage on the SAXS for samples with and without heat treatment (curves after 20 days and 6 months are not on the same scale);

Figure 12 shows the comparative effect of heat treatment on the particle size distribution of a liposomal sample; and

Figure 13 shows the comparative effect of heat treatment on the SAX pattern of a liposomal sample.

Examples:

The materials used in the following examples were as follows:

GMOrphic-80 (Eastman Kodak)
Myverol 18-99 (Eastman Kodak),
Rylo MG 19 (Danisco)
Dimodan DGMO (Danisco)
poloxamer 407 (Pluronic® F127, BASF)
poloxamer 188 (Pluronic® F68, BASF)
polysorbate 80 (Tween® 80, ICI)

Approximate compositions of the batches used are shown below in Table 1

Table 1

Trade Name	Composition %				
	Mono-glyceride	Di-glyceride	C18:1	Saturated	Higher unsaturated
GMOrphic-80 Lot No. D0116-1293 Batch No. 1997014177	≥ 94.0	?	≥ 75	≤ 10.0	≤ 15.0
Myverol 18-99 Batch No. 1996013291	≥ 90	?	60-65	5-7	ca. 30

Dimodan DGMO, NF Lot No. 70201	98	1.5	80	7.1	11.4
Rylo MG 19, NF Lot No. 2119/53	98.7	1.0	90.3	4.7	6.6

5

In the following examples the abbreviations used are:

	LD	Laser Diffraction particle size measurement
10	LM	Light microscopy
	LS	Light Scattering particle size measurement
	P407	poloxamer 407
	P188	poloxamer 188
	PCS	Photon Correlation Spectroscopy
15	PIDS	Polarisation Intensity Differential Scattering
	PSD	Particle Size Distribution
	SAXS	Small Angle X-ray Scattering
	TEM	Transmission Electron Microscopy

20 **Example 1 - forming a pre-formulation**

25 A coarse dispersion of largely cubic particles was formed by melting GMorphic-80 (1.84 g) with poloxamer 407 (0.16 g) and adding 1.25 g of the molten mixture dropwise to deionised water (23.75 g) (containing 0.01% thiomersal as preservative) under stirring at room temperature. The resulting coarse dispersion was allowed to equilibrate for at least about 1 day before homogenisation in a microfuidizer at high pressure (350
30 bar) for 15 min at 40°C.

All of the dispersions used in the following Examples were prepared according to this standard procedure

(Microfluidizer, 40°C, 350 bar, 15 min) with variations in composition (poloxamer/monoolein content and poloxamer/monoolein type) as specified. Where no specific poloxamer is indicated, poloxamer 407 was used.

5

Typical examples of the compositions prepared by this method are:

10	"8% P407":	Monoolein:	1.15 g	4.6 %
		Poloxamer 407:	0.10 g	0.4 %
		Water:	23.75 g	95.0 %
15	"12% P407":	Monoolein:	1.10 g	4.4 %
		Poloxamer 407:	0.15 g	0.6 %
		Water:	23.75 g	95.0 %
20	"8.75% P188":	Monoolein:	1.1406 g	4.6 %
		Poloxamer 188:	0.1094 g	0.4 %
		Water:	23.75 g	95.0 %

Example 2- Phase analysis of dispersion without heat treatment

25 A dispersion was prepared with Rylo MG19 and 12% poloxamer 407 (referring to the sum of monoolein and poloxamer). The resulting system was a slightly translucent homogenous dispersion, had particle sizes mainly around 0.09 μm (plus small amounts of particles around 0.3 μm) and displayed only extremely weak,
30 unassignable SAXS reflections. By Cryo-TEM, mainly small, lamellar particles were observed with a small proportion of non-lamellar particles (see Fig. 3). The smallest particles were all lamellar, but of the larger particles some displayed internal structure (possibly
35 cubic) and some did not.

Example 3 - Effect of Heat Treatment

A freshly prepared dispersion containing Rylo MG19 as monoolein and 12% poloxamer P407 was divided into two fractions. One fraction was autoclaved (121°C, 15 min (plus an equilibration time of 5 min, noted in the following as "(+5 min)", if applied)) and compared to the non-autoclaved fraction. The non-autoclaved fraction was comparable to Example 2, i.e. an opaque homogenous dispersion with particle sizes mainly around 0.09 μm (plus a small number of particles around 0.3 μm) (Fig. 1) and no SAXS reflections. The heat-treated fraction was milky-white (non-transparent) and LS+PIDS analysis (Fig. 1) gave a narrow monomodal particle size distribution (around 0.27 μm , without a smaller particle size fraction).

Clear SAXS reflections could be observed for the heat treated sample indicating the presence of cubic P phase. This indicates that the small non-cubic particles in the 0.1 μm range form larger, cubic particles in the medium sized range (ca. 0.3 μm) during the autoclaving process.

Cryo-TEM was performed on autoclaved fraction and compared to Example 2. Only a few small non-cubic particles could be detected after heat treatment. Most of the detectable particles are cubic and in the range of ca. 200-300 nm (Fig. 4). This result is in agreement with the SAXS- and LD+PIDS results of these dispersions: no cubic reflections and a particle size maximum at ca. 0.09 μm in the case of the non- autoclaved dispersion, reflections according to cubic phase type P and a particle size maximum at ca. 0.27 μm in the case of the autoclaved dispersion.

Similar behaviour was observed for a dispersion containing 8% poloxamer. In this case, the non-autoclaved dispersion is already milky white and

displays SAXS reflections (cubic P); the main particle size is in the range of 0.5 μm besides lesser amounts in the range of 0.1 μm and 1.5 μm . Like in the dispersion with 12% poloxamer, aggregates become observable by LM
5 after autoclaving, the small particles vanished and the amount of particles in the medium range increased in LD+PIDS analysis (Fig. 2).

Example 4 - Effect of Filtration

10

Four dispersions were prepared with 12% poloxamer, two of them with GMOrphic-80, the others with Rylo MG 19. In the case of GMOrphic, high pressure homogenization also led to opaque dispersions, similar to previous
15 experiments using Rylo. Fractions of these dispersions were filtered through a 0.45 μm membrane filter (filtration can easily be done by hand using a syringe) without any change in macroscopic appearance. The maximum particle size detected by LM was slightly
20 reduced. LD+PIDS give the same results for the filtered and the unfiltered dispersions, and SAXS reflections cannot be detected in any dispersion.

Samples of the filtered and unfiltered fractions were
25 autoclaved (121°C, 15(+5) minutes). In the filtered and the unfiltered cases, milky white dispersions were obtained with macroscopically visible particles. As in the case of the non-autoclaved dispersions, no clear differences can be detected between the filtered and
30 the not filtered dispersions after autoclaving.

Example 5 - Effect of Heat Treatment Time

A dispersion containing Myverol 18-99 as monoolein and
35 12% poloxamer was divided into four fractions. Three

fractions were autoclaved at 121°C for different periods of time (5 min, 15 min (+5 min), 30 min (+5 min)) and compared to the fourth, non-autoclaved fraction. During autoclaving, the opaque dispersion turned to milky white and visible aggregates appeared. In SAXS, the autoclaved dispersions display diffraction patterns according to the cubic P phase. In the case of the non-autoclaved dispersion no reflections can be detected, not even by the use of synchrotron radiation. LD+PIDS give monomodal particle size distributions for all dispersions, with a mode at ca. 360 to 390 nm for the autoclaved dispersions and a mode at ca. 88 nm for the non-autoclaved dispersion (Fig. 5). There are no detectable differences by any applied method between the autoclaved dispersions. Autoclaving time has thus no significant effect on the properties of the resulting dispersions in the range from 5 to 30(+5) minutes at this temperature.

Example 6 - Influence of Temperature

A dispersion containing Dimodan DGMO as monoolein was divided into four fractions. Two fractions were heated to 80°C for different periods of time (20 min and 60 min), one fraction was autoclaved (121°C / 15(+5) min) and one fraction was left unchanged. Autoclaving changed the dispersion from opaque to milky white, heating to 80°C led to nearly milky white dispersions (very slightly opaque) in both cases. The LD+PIDS results indicate that the particle size distributions slightly shifted to larger particles during heating to 80°C (Fig. 6); there is no difference between the two 80°C-dispersions (20 min and 60 min). A second dispersion with Dimodan from a different container (container 2, same batch) showed nearly the same particle size distribution in the unheated case (the

small peak at about 0.35 μm in the dispersion from container 1 is the averaging result of a bigger peak in one measurement run of five, the other runs showed the same particle size distribution as the dispersion from container 2), and increased particle sizes after autoclaving. Compared to autoclaving at 121°C, heating the dispersions to 80°C led to minor changes in particle size distribution (by means of LD+PIDS). In this case it therefore appears that temperatures higher than 80°C are necessary to form the large proportions of non-lamellar particles.

Example 7 - Influence of Monoolein Type

Autoclaving (121°C/15 min (+5 min)) dispersions containing 12% Poloxamer with GMOrphic-80 or Myverol 18-99, respectively, as monoolein leads to particle size distributions in a similar range. Also the particle size distributions of the corresponding non-autoclaved dispersions are comparable with each other. Even though the use of Dimodan DGMO leads to similar non-autoclaved dispersions, autoclaving of these dispersions leads to different, smaller particle sizes.

Example 8 - SAXS Experiments

SAXS experiments on the dispersions of the previous examples were performed. Generally the unheated/non-autoclaved dispersions containing 12% poloxamer did not display X-ray reflections and only in a few cases were extremely weak, unassignable reflections observed. The heated dispersions (80°C: 20 min and 60 min) display very weak reflections due to cubic P phase. In the case of the autoclaved dispersions (121°C, 5 min, 15 min and

30 min), weak reflections for the Dimodan dispersions and clear reflections for the GMOrphic and Myverol dispersions were obtained, all pointing to cubic P phase.

5

Example 9 - Further influence of temperature

For further investigation of the influence of the temperature applied during the heating process after homogenization, a dispersion containing GMOrphic-80 as monoolein (MO) and 12% P407 (based on the sum of MO and P407) was prepared according to the standard procedure (Example 1). Fractions of the homogenized dispersion were heated to 90°C, 100°C, 110°C and 121°C, respectively, for 20 minutes, and compared to a non-heated fraction (Fig. 7).

With increasing temperature, the mean particle size increases and the PSD becomes narrower. There is only a weak difference in the results obtained after heating to 110°C and 121°C, which lead to the assumption that heating to higher temperatures than 121°C will probably not result in a narrower PSD. After heating to 90°C, ca. 50% of the particles were larger than 0.2 μm and clear SAXS reflections (cubic P) were observed, in contrast to the result after heating to 80°C (see Example 6), where 90% of the particles remained smaller than 0.2 μm and only very weak SAXS reflections (probably cubic P) were detected. The non-heated fraction and the 121°C/15(+5)min fraction give the usual results obtained earlier. It was concluded that in this case the minimum temperature necessary for PSD narrowing and conversion to non-lamellar particles was in the region of 90°C.

35

Example 10 - Influence of poloxamer concentration

For testing the influence of poloxamer 407 concentrations above 12% on the effect of autoclaving, 5 dispersions containing 12%, 14% and 16% P407 were prepared according to the standard procedure. Fractions of these dispersions were autoclaved (121°C/15(+5) min) and compared to the non-autoclaved fractions (Fig. 8).

10 In both cases (autoclaved and non-autoclaved), no difference can be detected between the 12% dispersion and the dispersions with higher concentrations of P407 by visual inspection, light microscopy and SAXS. All of the non-autoclaved dispersions were opaque and displayed 15 no SAXS reflections. After autoclaving, they turned into milky-white dispersions with large aggregates, and displayed clear SAXS reflections according to cubic P with nearly the same lattice constants.

20 The LD+PIDS results demonstrate that increasing the P407-concentration from 12% to 14% slightly reduces the fraction of particles in the 0.2 - 0.5 μm range in the non-autoclaved dispersions. Further increasing of the P407-concentration had no effect on the LD+PIDS result. 25 The mode value and the width of the PSD for the autoclaved dispersion are slightly different for the different P407-concentrations despite the fact that they were autoclaved together by the same autoclaving process. No correlation was seen between 30 P407-concentration and PSD mode value or PSD width.

Example 11 Influence of poloxamer type

To test the influence of the poloxamer type on the 35 properties of the resulting dispersions, poloxamer 188

(P188) was used instead of P407. A dispersion was prepared according to the standard procedure (Example 1) with P188-concentrations of 8.75 weight-% (based on the sum of MO and P188). This concentration of P188 is equivalent (when calculated as mol-%) to the usual concentrations of P407 (12 weight-%). Fractions of this dispersion were autoclaved (121°C/15(+5) min). The dispersion was compared to a non-autoclaved and autoclaved dispersion with 12% P407 (Fig. 9).

10

The homogenized (non-autoclaved) dispersion with 8.75% P188 was homogenous and nearly milky white. SAXS reflections were not detected and LD+PIDS displayed a PSD with a slightly higher amount of particles in the size range of ca. 0.2 - 0.5 μm compared to the non-autoclaved dispersion with 12% P407. The autoclaved fraction of this dispersion was milky-white with large aggregates and displayed clear cubic P SAXS reflections, like the autoclaved dispersion with 12% P407 do (see Fig. 10). A very weak peak in the autoclaved 8.75% P188-dispersion between the first and the second cubic P reflection is in the region where the first reflection of a cubic D phase would be expected and may indicate a small amount of cubic D phase in this dispersion. The lattice constant (of the cubic P phase) is smaller in the case of the dispersion containing 8.75% P188 (ca. 13.5 nm) compared to that of the dispersion containing 12% P407 (ca. 14.4 nm). The PSD (LD+PIDS) was nearly the same as that of the autoclaved dispersion with 12% P407.

30

Example 12 - Influence of long-term storage

To answer the question, whether the lamellar particles of a non-autoclaved dispersion with 12% P407 transform into non-lamellar particles with time without heat

35

treatment, or whether the cubic particles produced by autoclaving a dispersion with 12% P407 transform back to lamellar particles with time, dispersions (12% P407, non-autoclaved and autoclaved) were investigated by SAXS after a storage period of 6 months (at 23°C, called "stored dispersions") after preparation. The results were compared to the SAXS results of these dispersions obtained 20 days (stored at 23°C, called "unstored dispersions") after preparation (Fig. 11).

In the case of the autoclaved dispersion, the diffractograms of both dispersions (stored and unstored) display clear cubic P reflections, the lattice constants are the same (14.4 nm). No additional reflections occur after storage (a phase change to cubic D or hexagonal with time, possibly caused by, e.g., hydrolysis of the monoolein, would result in additional reflections).

In the case of the non-autoclaved dispersion, there are no reflections detectable in the diffractograms of either system. The result, that no detectable cubic P phase is formed in non-autoclaved dispersions (with 12% P407) by time, was confirmed by examination of a second, independent batch (after 7 days and 6 months after preparation).

Example 13 - Influence of Drug Loading

Five different drugs (ubidecarenone, tocopherol acetate, miconazole, betamethasone-17-valerate, chloramphenicol) were incorporated in a monoolein (GMORphic) dispersion stabilized with 12 % P407 (which forms a lamellar vesicular dispersion in the unloaded state) by adding the drugs to the MO/P407 melt at 60°C (or 80°C for concentrations of 5 % drug) in the "standard"

preparation process (see Example 1). All drug concentrations are indicated relative to the sum of monoglyceride and poloxamer. A drug-free dispersion was prepared and investigated as a reference.

5

All dispersions were autoclaved at 121°C for 15 + 5 min. (allowing for temperature equilibration in the autoclave) and their properties were compared to that of the corresponding non-autoclaved dispersions.

10

Ubidecarenone and tocopherol acetate at a concentration of 0.3 % did not influence the properties of the resulting dispersions. The transformation of lamellar vesicular into non-lamellar (cubic) particles upon autoclaving proceeded as in the drug-free dispersions. Higher concentrations of these drugs were not investigated.

15

Dispersions with 0.3, 1 or 2 % betamethasone-17-valerate also had no influence on the general behaviour of the dispersions. A drug load of 5 % could not be realized with this substance since it could not be dissolved in the MO/P407 melt at this concentration.

20

Chloramphenicol at 0.3, 1 and 2 % as well as miconazole at 0.3 and 1 % had no influence on the non-autoclaved dispersions. In autoclaved dispersions, however, a concentration dependent influence could be observed: In chloramphenicol-loaded dispersions the particle sizes increased distinctly with drug concentration and a slight increase in lattice constant of the cubic phase was observed. 5 % chloramphenicol could be incorporated in the MO-dispersion but homogenization as well as autoclaving led to dispersions with distinctly larger particle sizes in comparison to the drug free

25

30

35

dispersions and those with up to 2 % drug.

For the 5 % chloramphenicol sample, cubic reflections could be observed in small angle X-ray scattering even before autoclaving. The lattice constant of the cubic phase in the (non-autoclaved and autoclaved) 5 % sample is much larger than in the autoclaved drug-free dispersion or (autoclaved) dispersions with up to 2 % chloramphenicol.

Miconazole could be incorporated at concentrations of 0.3 and 1%. Homogenization of these dispersions led to opaque dispersions without cubic X-ray reflections in all cases. Autoclaving led to slightly larger (0.3 %) and distinctly larger (1 %) particle sizes compared to the dispersions without drug incorporation. The lattice constant decreased slightly.

Example 14 Autoclaving of a liposomal dispersion

In order to assess whether a standard liposomal dispersion having a lamellar equilibrium form at room temperature would convert to non-lamellar particles under heating, the method was tested on a liposomal dispersion.

To prepare the liposomal dispersion, 5 % egg phospholipid (Lipoid E80) was stirred in water (containing 0.01 % thiomersal as a preservative) for one day at room temperature and subsequently extruded (Avestin Emulsiflex-C5) 10 times through a 100 nm polycarbonate filter. The resulting dispersion had a PCS z-average diameter of 117 nm with a polydispersity index of 0.08.

One fraction of the dispersion was autoclaved for 15 + 5

min. at 121°C and the properties of the resulting dispersion were compared to that of the non-autoclaved one. Except for slight differences in optical appearance no differences between the two samples were observed with the following methods:

Both samples are visually homogenous without macroscopically detectable particles and of yellowish-opaque appearance with a slightly more intense colour after autoclaving. The particle size measurement with laser diffraction + PIDS yields a monomodal particle size distribution with a mode at 106 nm for both dispersions (Fig. 12). Both dispersions display diffuse small angle X-ray scattering without detectable sharp reflections, indicating the presence of only lamellar particles (Fig. 13).

Claims

1. A method for the production of (preferably colloidal) non-lamellar particles, said method
5 comprising forming lamellar and optionally non-lamellar particles comprising at least one structuring agent, heating said particles to an elevated temperature, followed by cooling, preferably to ambient temperature, wherein said heating is to a temperature and for a
10 period sufficient to provide conversion of at least 50% of said lamellar particles to non-lamellar form, after cooling.
2. A method for narrowing the particle size
15 distribution of a sample of lamellar and/or non-lamellar particles comprising at least one structuring agent, said method comprising heating said particles to an elevated temperature, followed by cooling, preferably to ambient temperature, wherein said heating is to a
20 temperature and for a period sufficient to provide a narrowing of said particle size distribution, after cooling.
3. Non-lamellar particles comprising at least one
25 structuring agent formed or formable by forming lamellar and optionally non-lamellar particles comprising at least one structuring agent, heating said particles to an elevated temperature, followed by cooling, preferably to ambient temperature, wherein said heating is to a
30 temperature and for a period sufficient to provide conversion of at least 50% of said lamellar particles to non-lamellar form, after cooling.
4. A formulation of (preferably colloidal) particles
35 comprising at least one structuring agent, wherein at

least 75% of the particles, preferably at least 85% and most preferably at least 95% of particles in the formulation are non-lamellar.

- 5 5. A formulation as claimed in claim 4 further comprising at least one active agent.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10

I [a.u.]




Figure 11




Figure 12




Figure 13

PCT/GB2004/003398



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.